Manulife (Manufacturers Life Insurance)
DYN icon

Manulife (Manufacturers Life Insurance)’s Dyne Therapeutics DYN Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Sell
63,850
-3,657
-5% -$63.1K ﹤0.01% 1758
2025
Q4 		$1.32M Buy
67,507
+10,164
+18% +$192K ﹤0.01% 1716
2025
Q3 		$725K Buy
57,343
+7,457
+15% +$85K ﹤0.01% 2037
2025
Q2 		$475K Buy
49,886
+10,022
+25% +$110K ﹤0.01% 2199
2025
Q1 		$417K Sell
39,864
-57,531
-59% -$823K ﹤0.01% 2230
2024
Q4 		$2.29M Sell
97,395
-8,820
-8% -$261K ﹤0.01% 1501
2024
Q3 		$3.82M Sell
106,215
-20,029
-16% -$797K ﹤0.01% 1323
2024
Q2 		$4.46M Buy
126,244
+61,902
+96% +$1.8M ﹤0.01% 1215
2024
Q1 		$1.83M Buy
64,342
+47,013
+271% +$1.06M ﹤0.01% 1549
2023
Q4 		$230K Sell
17,329
-7,800
-31% -$76.2K ﹤0.01% 2542
2023
Q3 		$225K Buy
25,129
+7,848
+45% +$84.5K ﹤0.01% 2525
2023
Q2 		$194K Sell
17,281
-9,239
-35% -$109K ﹤0.01% 2622
2023
Q1 		$306K Buy
26,520
+13,700
+107% +$178K ﹤0.01% 2295
2022
Q4 		$149K Sell
12,820
-557
-4% -$6.45K ﹤0.01% 2684
2022
Q3 		$170K Sell
13,377
-909
-6% -$10.4K ﹤0.01% 2657
2022
Q2 		$98.1K Buy
14,286
+859
+6% +$5.92K ﹤0.01% 2912
2022
Q1 		$129K Sell
13,427
-3,721
-22% -$31.7K ﹤0.01% 2913
2021
Q4 		$204 Buy
17,148
+978
+6% +$13.7K ﹤0.01% 2878
2021
Q3 		$263K Sell
16,170
-841
-5% -$14.9K ﹤0.01% 2776
2021
Q2 		$358K Buy
+17,011
New +$320K ﹤0.01% 2678

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s DYN Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Dyne Therapeutics (DYN) stake by 5.4% in Q1 2026, selling an estimated $63.1K and leaving 63,850 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1758.

Manulife (Manufacturers Life Insurance) first reported a position in DYN in Q2 2021 and has held it in 20 quarters since. The position peaked at $4.46M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 63,850 shares of Dyne Therapeutics worth $1.16M as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 3,657 Dyne Therapeutics shares in Q1 2026, an estimated $63.1K.
  • Dyne Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1758 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Dyne Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Dyne Therapeutics position peaked at $4.46M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.